Allergy Impact Factor

That places Allergy at the top of its JCR category in the current cycle.

The journal's rank matters as much as the headline number. A 11.3 JIF in a narrow, high-quality specialty lane means something different from a 11.3 at a broad multidisciplinary venue.

Here, the signal is reinforced by the JCI of 2.08. The journal is performing well above category average after normalization, which matters in allergy and immunology because citation behavior differs a lot across subfields.

The smaller but still useful detail is that the two-year JIF is slightly higher than the five-year JIF. That usually means the recent citation cycle has been especially strong. In Allergy, that makes sense. The field has been moving fast around endotypes, biologics, severe asthma, atopic dermatitis, food allergy, and immunotherapy.

Because Allergy is a specialty clinical journal, the JCR rank is the main placement signal. The table below uses Resurchify's Scopus impact-score history only to show whether recent specialty citation demand is holding.

Directionally, the open citation signal is up from 6.86 in 2023 to 7.54 in 2024. More importantly, the journal has stayed strong across a full decade rather than relying on one extraordinary spike.

That is what you want to see in a specialty clinical journal. The number is high because the journal remains central to a real field, not because of one temporary attention cycle.

Use this table to avoid a common source mistake. The JIF and JCR category rank answer citation standing; Wiley and the live journal pages answer article types, submission mechanics, OA fees, and publication policies.

The common mistake is to see a top-ranked allergy journal and assume any high-quality immunology paper is worth the shot.

That is usually wrong. Allergy is still a readership-specific journal. The paper generally needs to matter for:

• allergic disease mechanisms

• asthma or airway inflammation with real allergy relevance

• biomarker or endotype work that changes interpretation or management

• immunotherapy, biologics, or clinically meaningful translational allergy science

If allergic disease is just the setting rather than the scientific center, the fit weakens fast.

In our pre-submission review work for Allergy, we see the main misses are usually not formatting mistakes. They are fit mistakes visible in the title, abstract, cohort definition, first figure, and cover letter. The science may be real, but the manuscript can still read like a general immunology paper with allergy terminology layered on top.

The manuscript is immunology-first and allergy-second. The pathway work may be sound, but the allergic-disease consequence is too thin for the journal's readership. The quick test is whether the abstract would still make sense if every allergy-specific disease word were replaced with a broader immune-disease label. If yes, the venue case is weak.

Clinical phenotype definition is weak. Biomarker and cohort papers often fail because the disease classification, comparator groups, exposure history, treatment state, or outcome framing cannot support the clinical claim. Allergy readers need to see why the phenotype is not just convenient, but essential to the conclusion.

The translational bridge is missing from the design. Mechanistic animal or cell work can be interesting and still fail if there is no believable path to patient meaning. A late discussion paragraph about possible clinical relevance does not substitute for patient samples, clinical endpoints, human cell validation, or a clear disease-mechanism bridge.

The paper describes associations without changing decisions. This shows up in asthma, food allergy, atopic dermatitis, allergic rhinitis, and urticaria studies where the statistics are clean but the result does not change diagnosis, stratification, treatment choice, risk prediction, or mechanistic interpretation.

Recent article identity checks help ground that distinction. Allergy's current issue surface includes DOI-linked clinical-allergy and guideline-style papers such as 10.1111/all.16502, 10.1111/all.70078, and 10.1111/all.70070. Those are not templates for every submission, but they show the kind of disease-specific framing authors should compare against before using the 11.3 JIF as a target-selection argument.

If that sounds familiar, an Allergy submission readiness check is often more valuable than another abstract rewrite.

The impact factor does not tell you whether the journal will treat your endpoint, phenotype definition, or translational bridge as clinically meaningful enough. Allergy is still a field journal with strong editorial taste. Papers that are technically sound but vague about patient relevance often underperform at first decision.

That is why the metric is most useful as a placement tool, not a submission excuse. It tells you the journal matters. It does not tell you your manuscript speaks the language of allergy specialists strongly enough to belong there.

It also does not tell you whether the paper feels current enough for a fast-moving biologics and endotype field.

When the paper is in reviewers' hands, the Allergy Under Review status guide lays out the typical timeline and how to read a label that has not moved.